School of Medicine, Ningbo University, Ningbo 315211, China.
School of Medicine, Ningbo University, Ningbo 315211, China; Department of Histology and Embryology, Harbin Medical University, Harbin 150081, China.
Int Immunopharmacol. 2022 Aug;109:108842. doi: 10.1016/j.intimp.2022.108842. Epub 2022 May 12.
Chronic hepatitis B (CHB) is a contagious disease caused by the hepatitis B virus, which can damage the liver via cirrhosis or cancer. Existing CHB treatments are not completely effective; immune checkpoint inhibitors show potential hope for treating CHB, but their safety and efficacy need to be further validated. In this review, we introduce the mechanisms of CHB virus infection, the expression of immune checkpoints during CHB, and the treatments that are currently available. Finally, we discuss the possibilities for using immune checkpoint inhibitors to treat CHB.
慢性乙型肝炎（CHB）是由乙型肝炎病毒引起的传染病，可通过肝硬化或癌症损害肝脏。现有的 CHB 治疗方法并不完全有效；免疫检查点抑制剂为治疗 CHB 带来了新的希望，但它们的安全性和疗效仍需进一步验证。本综述介绍了乙型肝炎病毒感染的机制、CHB 期间免疫检查点的表达以及目前可用的治疗方法。最后，我们讨论了使用免疫检查点抑制剂治疗 CHB 的可能性。
